CTPS1 inhibition suppresses proliferation and migration in colorectal cancer cells

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Lin JS, Piper MA, Perdue LA, et al. Screening for Colorectal Cancer: updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Jama. 2016;315(23):2576–2594.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. Cancer J Clin. 2019;69(5):363–385.
   PubMed Web of Science ®Google Scholar
• Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637–1649.
   PubMed Web of Science ®Google Scholar
• Fung KY, Nice E, Priebe I, et al. Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled. World J Gastroenterol. 2014;20(4):888–898.
   PubMed Web of Science ®Google Scholar
• Liu L, He Q, Li Y, et al. Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer. Clin Chim Acta. 2020;509:36–42.
   PubMed Web of Science ®Google Scholar
• Werner S, Krause F, Rolny V, et al. Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting. Clin Cancer Res. 2016;22(7):1725–1733.
   PubMed Web of Science ®Google Scholar
• Moschetta M, Uccello M, Kasenda B, et al. Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade. Biomed Res Int. 2017;2017:1506824.
   PubMed Web of Science ®Google Scholar
• Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem. 1994;140(1):1–22.
   PubMed Web of Science ®Google Scholar
• Williams JC, Kizaki H, Weber G, et al. Increased CTP synthetase activity in cancer cells. Nature. 1978;271(5640):71–73.
   PubMed Web of Science ®Google Scholar
• Politi PM, Xie F, Dahut W, et al. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol. 1995;36(6):513–523.
   PubMed Web of Science ®Google Scholar
• Kassel KM, Higgins R, Hines MJ, et al. Regulation of human cytidine triphosphate synthetase 2 by phosphorylation. J Biol Chem. 2010;285(44):33727–33736.
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Meinsma R, Vreken P, et al. Isoforms of human CTP synthetase. Adv Exp Med Biol. 2000;486:257–261.
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Meinsma R, Vreken P, et al. Identification of a cDNA encoding an isoform of human CTP synthetase. Biochim Biophys Acta. 2000;1492(2–3):548–552.
   PubMedGoogle Scholar
• Kursula P, Flodin S, Ehn M, et al. Structure of the synthetase domain of human CTP synthetase, a target for anticancer therapy. Acta Crystallogr. 2006;62(Pt 7):613–617.
   Google Scholar
• Winter S, Martin E, Boutboul D, et al. Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility. EMBO Mol Med. 2018;10(2):188–199.
   PubMed Web of Science ®Google Scholar
• Qu H, Chen Y, Cao G, et al. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics. Oncotarget. 2016;7(50):83187–83199.
   PubMedGoogle Scholar
• Kursunel MA, Esendagli G. The untold story of IFN-γ in cancer biology. Cytokine Growth Factor Rev. 2016;31:73–81.
   PubMed Web of Science ®Google Scholar
• Cao W, Jiang Y, Ji X, et al. Identification of novel prognostic genes of triple-negative breast cancer using meta-analysis and weighted gene co-expressed network analysis. Ann Transl Med. 2021;9(3):205.
   PubMed Web of Science ®Google Scholar
• Ohmine K, Kawaguchi K, Ohtsuki S, et al. Quantitative Targeted Proteomics of Pancreatic Cancer: deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment. Mol Pharm. 2015;12(9):3282–3291.
   PubMed Web of Science ®Google Scholar
• Martin E, Palmic N, Sanquer S, et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature. 2014;510(7504):288–292.
   PubMed Web of Science ®Google Scholar
• Martin E, Minet N, Boschat AC, et al. Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation. JCI Insight. 2020;5(5). DOI:10.1172/jci.insight.133880
   Web of Science ®Google Scholar
• Boussios S, Ozturk MA, Moschetta M, et al. The Developing Story of Predictive Biomarkers in Colorectal Cancer. J Pers Med. 2019;9:1.
   PubMed Web of Science ®Google Scholar
• Long CW, Levitzki A, Koshland DE Jr. The subunit structure and subunit interactions of cytidine triphosphate synthetase. J Biol Chem. 1970;245(1):80–87.
   PubMed Web of Science ®Google Scholar
• Ostrander DB, O’Brien DJ, Gorman JA, et al. Effect of CTP synthetase regulation by CTP on phospholipid synthesis in Saccharomyces cerevisiae. J Biol Chem. 1998;273(30):18992–19001.
   PubMed Web of Science ®Google Scholar
• Sun Z, Zhang Z, Wang QQ, et al. Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells. Cancer Res. 2022;82(6):1013–1024.
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhang J, Li Y, et al. CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1. J Transl Med. 2022;20(1):17.
   PubMed Web of Science ®Google Scholar
• Bublik DR, Scolz M, Triolo G, et al. Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment. J Biol Chem. 2010;285(8):5274–5281.
   PubMed Web of Science ®Google Scholar
• Utrera R, Collavin L, Lazarević D, et al. A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. EMBO J. 1998;17(17):5015–5025.
   PubMed Web of Science ®Google Scholar
• Lin F, Xie YJ, Zhang XK, et al. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner. J Exp Clin Cancer Res. 2019;38(1):152.
   PubMedGoogle Scholar
• Subhash VV, Tan SH, Tan WL, et al. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer. 2015;15:550.
   PubMed Web of Science ®Google Scholar
• Wu X, Wang H, Lian Y, et al. GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis. Sci Rep. 2017;7(1):5129.
   PubMedGoogle Scholar
• Dulić V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science. 1992;257(5078):1958–1961.
   PubMed Web of Science ®Google Scholar
• Ohtsubo M, Theodoras AM, Schumacher J, et al. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 1995;15(5):2612–2624.
   PubMed Web of Science ®Google Scholar
• Tadesse S, Anshabo AT, Portman N, et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today. 2020;25(2):406–413.
   PubMed Web of Science ®Google Scholar
• Joerger AC, Fersht AR. The p53 Pathway: origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu Rev Biochem. 2016;85(1):375–404.
   PubMedGoogle Scholar
• Blagih J, Buck MD, Vousden K. H., p53, cancer and the immune response. J Cell Sci. 2020;133(5). DOI:10.1242/jcs.237453
   PubMed Web of Science ®Google Scholar